WASHINGTON, March 31 (Reuters) - Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.
The Patent Trial and Appeal Board rejected a challenge to three Teva patents relating to Ajovy brought by Eli Lilly and Co .
Reporting by Jan Wolfe; Editing by Cynthia Osterman
Our Standards: The Thomson Reuters Trust Principles.